Aptevo presents preclinical data showing immunotherapy efficacy under tumor suppression
Aptevo Therapeutics Inc. unveiled preclinical data at SITC 2026 demonstrating that its novel antibody-like molecules stimulate T-cells and kill cancer cells even in immunosuppressive conditions, potentially addressing a major barrier in solid tumor immunotherapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed